TrialPath
Recruiting

ATR 1072 in Participants With PRKAG2 Syndrome

NCT07738107 · Atrium Therapeutics
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase 1/2, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous ATR 1072 for the Treatment of PRKAG2 Syndrome
About this study
ATR 1072 is an antibody-oligonucleotide conjugate (AOC) designed to reduce expression of PRKAG2 through targeted delivery of siRNA to cardiac tissue. This first-in-human, Phase 1/2, open-label, multicenter study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of multiple doses of ATR 1072 in adults with PRKAG2 Syndrome. The study consists of a multiple ascending dose portion (Part A) followed by a dose-expansion cohort at the dose selected in (Part A). After completion of a 48-week treatment period, participants in Parts A and B enter a 42-week extension period followed by a post-treatment follow-up of up to 18 weeks. Approximately 37 participants will be enrolled globally.
Eligibility criteria
Inclusion Criteria: 1. Adults 18 to 65 years of age. 2. Pathogenic, likely pathogenic, or variant of uncertain significance (VUS) in PRKAG2 confirmed by genetic testing. 3. Clinical manifestations consistent with PRKAG2 Syndrome. 4. Able and willing to comply with study procedures. 5. Able and willing to undergo endomyocardial biopsy procedures (Part A) Exclusion Criteria: 1. Pregnancy or breastfeeding. 2. Significant hepatic, renal, hematologic, or cardiovascular abnormalities that may increase study risk. 3. NYHA Class IV heart failure or left ventricular ejection fraction \<45%. 4. Recent clinically significant cardiovascular events or procedures. 5. Prior treatment with prohibited investigational therapies or oligonucleotide therapies within protocol-defined washout periods. 6. Any condition that, in the investigator's
Study design
Enrollment target: 37 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-09-14
Estimated completion: 2028-10
Last updated: 2026-11-19
Interventions
Drug: ATR 1072
Primary outcomes
  • • Incidence of treatment-emergent adverse events (TEAEs) (From first dose through end of study (approximately 48 weeks per participant))
Sponsor
Atrium Therapeutics · industry
Contacts & investigators
ContactPatient Recruitment Coordinator · contact · clinicaltrials@atrium-tx.com · 283-227-6543
All locations (2)
St Luke's Mid American Heart InstituteRecruiting
Kansas City, Missouri, United States
Houston MethodistRecruiting
Houston, Texas, United States
ATR 1072 in Participants With PRKAG2 Syndrome · TrialPath